Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record.

Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer

Open access
Wang, Fubo, Ren, Shancheng, Chen, Rui, Lu, Ji, Shi, Xiaolei, Zhu, Yasheng, Zhang, Wei, Jing, Taile, Zhang, Chao, Shen, Jian, Xu, Chuanliang, Wang, Huiqing, Wang, Haifeng, Wang, Yang, Liu, Bin, Li, Yaoming, Fang, Ziyu, Guo, Fei, Qiao, Meng, Wu, Chengyao, Wei, Qiang, Xu, Danfeng, Shen, Dan, Lu, Xin, Gao, Xu, Hou, Jianguo, Sun, Yinghao·2014·Oncotarget

Abstract

// Fubo Wang 1,* , Shancheng Ren 1,* , Rui Chen 1,* , Ji Lu 1 , Xiaolei Shi 1 , Yasheng Zhu 1 , Wei Zhang 1 , Taile Jing 1 , Chao Zhang 1 , Jian Shen 1,2 , Chuanliang Xu 1 , Huiqing Wang 1 , Haifeng Wang 1 , Yang Wang 3 , Bin Liu 1 , Yaoming Li 1 , Ziyu Fang 1 , Fei Guo 1 , Meng Qiao 1 , Chengyao Wu 1 , Qiang Wei 4 , Danfeng Xu 5 , Dan Shen 1 , Xin Lu 1 , Xu Gao 1 , Jianguo Hou 1 and Yinghao Sun 1 1 Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China 2 Department of Urology, Changshu NO. 2 People’s Hospital, Changshu, Jiangsu Province, China 3 Department of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China 4 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China 5 Department of Urology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China * These authors contributed equally to this work Correspondence: Yinghao Sun, email: // Keywords : prostate cancer, urine, biomarker, prostate biopsy, PSA, MALAT-1 Received : August 24, 2014 Accepted : November 04, 2014 Published : November 04, 2014 Abstract The current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and has led to numerous unnecessary biopsies. We evaluated the effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long noncoding RNA, for predicting the risk of PCa before biopsy. The MALAT-1 score was tested in a discovery phase and a multi-center validation phase. The predictive power of the MALAT-1 score was evaluated by the area under receiver operating characteristic (ROC) curve (AUC) and by decision curve analysis. As an independent predictor of PCa, the MALAT-1 score was significantly higher in men with a positive biopsy than in those with a negative biopsy. The ROC analysis showed a higher AUC for the MALAT-1 score (0.670 and 0.742) vs. the total PSA (0.545 and 0.601) and percent free PSA (0.622 and 0.627) in patients with PSA values of 4.0-10 ng/ml. According to the decision curve analysis, using a probability threshold of 25%, the MALAT-1 model would prevent 30.2%-46.5% of unnecessary biopsies in PSA 4–10 ng/ml cohorts, without missing any high-grade cancers. Our results demonstrate that urine MALAT-1 is a promising biomarker for predicting prostate cancer risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2691

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Wang, F., Ren, S., Chen, R., Lu, J., Shi, X., Zhu, Y., Zhang, W., Jing, T., Zhang, C., Shen, J., Xu, C., Wang, H., Wang, H., Wang, Y., Liu, B., Li, Y., Fang, Z., Guo, F., Qiao, M., Wu, C., Wei, Q., Xu, D., Shen, D., Lu, X., Gao, X., Hou, J., & Sun, Y.
Venue
Oncotarget
Published
2014-11-04
Volume
5
Issue
22
Pages
11091-11102
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1888195090
Cited by
180
References
0
FWCI
5.93
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.